OncLive SOSS

Authors

Naseema Gangat, MBBS

Latest:

Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

Panelists discuss monitoring parameters when treating patients with polycythemia vera (PV), including what to assess, typical outcomes, and when treatment should be switched due to ineffectiveness. Dr Kuykendall to Dr Gangat: Panelists explore the risk of PV progression/transformation, risk factors for progression, and how the data influence patient care and treatment choices in practice.

Roman Groisberg, MD

Latest:

Sarcoma, the “Forgotten Cancer”: Examining What’s Needed to Improve Care

Sarcomas, all together, have an incidence of less than 5/100,000 persons per year, according to the Surveillance, Epidemiology, and End Results Program. Compare that with breast cancer, which impacts 129.1/100,000 women per year, or lung cancer, which has an incidence of 53.1/100,000 persons per year

Latest:

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Latest:

Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease

Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disease.

R. Alejandro Sica, MD

Latest:

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Grace Elsey, PharmD

Latest:

The Potential of Modified Treatment Regimens in AYA ALL

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

Konstantinos Leventakos, MD, PhD Mayo Clinic

Latest:

Novel Treatment Approaches for SCLC and Future Perspectives

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Rutgers Cancer Institute of New Jersey

Latest:

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer Center

Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.

Sameh R. Gaballa, MD, Moffitt Cancer Center

Latest:

Patient Scenario 2: A 53-Year-Old Man With Relapsed/Refractory FL

Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.

Michael L. Grossbard, MD

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center

Latest:

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Ana Velázquez Mañana, MD

Latest:

Dr Velázquez Mañana on Survivorship Care Needs in Older Patients With Lung Cancer

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.

Do-Youn Oh, MD, PhD

Latest:

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Angela J. Keleher, MD, FACS

Latest:

Let’s Talk About Post-Mastectomy Chest Numbness

Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.

J. Nicholas Bodor, MD, PhD, MPH

Latest:

Dr Bodor on a Study Profiling Estrogen Species in Women With EGFR-Mutated NSCLC

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Winship Cancer Institute

Latest:

The American Cancer Society, Winship Partner to Accelerate Cancer Research in Georgia

The American Cancer Society, in partnership with Winship Cancer Institute of Emory University, announced a new project that aims to significantly accelerate cancer research and improve patient outcomes.

Aditya Bardia, MD, Massachusetts General Hospital Cancer Center

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

Justine Kahn, MD, MS

Latest:

Dr. Kahn on the Importance of Diverse Clinical Trial Participation in Oncology

Justine Kahn, MD, MS, discusses the importance of diverse clinical trial participation within the oncology space.

Ryotaro Nakamura, MD, City of Hope

Latest:

Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Dan Pollyea, MD, MS

Latest:

Dr. Pollyea on the Role of Maintenance Therapy in AML

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.